Updated:
Forward Equity Partners
Forward Equity Partners | A cross-border private equity firm focused on global healthcare and life sciences investments We partner with innovative...
Forward Equity Partners
Forward Equity Partners | A cross-border private equity firm focused on global healthcare and life sciences investments We partner with innovative companies developing essential technologies and infrastructure that advance human health
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seoul
Corporate office
Due Building 10F, 543 Bongeunsa-ro, Gangnam-gu, Seoul, South Korea
Principals
Paul H. Kim
CEO & Managing Director
Alain Schreiber
Hong Jun Park
Alain Rolland
Sector focus
Frequently asked questions
Who runs investment decisions at Forward Equity Partners?
Paul H. Kim, CEO and Managing Director, runs investment decisions at Forward Equity Partners. He founded the firm as Medivate Partners and continues to lead the team. Other named industry veterans include Alain Schreiber, Hong Jun Park, and Alain Rolland, but the firm's public materials designate Kim as the primary decision-maker.
Is Forward Equity Partners a single family office or a private equity firm?
Forward Equity Partners operates as a private equity firm, not a family office. It structures itself as an asset manager making buyout, growth, and pre-IPO investments, and it co-invests alongside syndicate partners and other co-GPs.
How does Forward Equity Partners source its deals?
Forward sources deals through its trans-Pacific network, originating healthcare and life-sciences investments in the US and connecting them with Korean institutional and domestic investors. Its website emphasizes a partnership model with co-GPs and syndicate partners that channel capital into US-based healthcare assets.
What investment stages does Forward Equity Partners target?
Forward targets buyout, growth, and pre-IPO stages. Its portfolio spans early-stage clinical research organizations to commercial-scale contract development and manufacturing companies, as well as Series A through convertible-note rounds in biotech platforms.
Which sectors does Forward Equity Partners explicitly avoid?
Forward's public disclosures do not explicitly list excluded sectors. The firm focuses narrowly on healthcare and life sciences — including biotech, CDMOs, CROs, and novel drug platforms — and has not announced investments outside those verticals.
Does Forward Equity Partners participate in fund commitments or only direct deals?
Based on available disclosures, Forward executes direct deals rather than fund commitments. Its portfolio page lists equity and convertible-note positions in operating companies, and its website describes a co-GP and syndicate model for connecting investors to direct US healthcare opportunities.
How is Forward Equity Partners related to Medivate Partners?
Medivate Partners is the predecessor firm founded by Paul Kim. Forward Equity Partners is the current operating name and corporate identity, with Kim continuing as CEO and Managing Director. The firm’s portfolio page notes that 'formerly as Medivate Partners, Forward has invested in unique, disruptive biotech/healthcare companies.'
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: